Biogen buys Tysabri from Elan for $3.25bn


US biotech Biogen Idec is to pay $3.25 billion (£2 billion) to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis (MS).

The drug is currently marketed jointly by the two companies, with profits split evenly. It generated $1.6 billion in sales in 2012, up 8% compared with 2011, and accounted for almost all the sales at Elan.

Under the terms, Biogen Idec will pay $3.25 billion up front in order to take full ownership of the blockbuster drug and agree to make future payments linked to sales.

The deal ‘provides for a meaningful de-risking of the business’, said Elan chief executive Kelly Martin. ‘As we move through 2013 and beyond, the close of the Tysabri transaction gives us strategic flexibility to add to the shareholder value proposition and investment thesis by enabling continued prudent and risk justified investment in our pipeline, selectively adding commercial and clinical assets, and exploring the return of capital to shareholders at the appropriate time and in the right manner.’


Related Content

Talk of a $6.6bn deal for Elan

27 February 2013 Business

news image

Potential offer from Royalty Pharma comes as Elan ponders how to spend its cash from Tysabri rights

Perrigo bags Elan and its bargain Irish tax rates

31 July 2013 Business

news image

$8.6bn deal ends Elan’s takeover battle with Royalty Pharma

Most Read

Higher levels of some metals in e-cigarette smoke

8 September 2014 Research

news image

Scientists call for regulators to help clear smoke and mirrors surrounding vaping safety

Isotope effect produces new type of chemical bond

22 October 2014 Research

news image

Evidence emerges for vibrational bond first proposed 30 years ago

Most Commented

Indian U-turn on diabetes drug ban

16 August 2013 News and Analysis

news image

Suspension of cheap and popular medicine reversed but will now come with new safety warnings

DNA waves don't wash

10 July 2013 The Crucible

news image

Philip Ball asks why a spectacular claim seems to have been overlooked. Sometimes science doesn’t work the way it’s suppo...